Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004570 · ClinicalTrials.gov registry record

Hereditary Deficits in Auditory Processing Leading to Language Impairment

A clinical trial, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).

Terminated
Registry status
875
Enrollment target

NCT00004570: Clinical Trial study, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).

NCT00004570 is a clinical trial that was terminated before completion, run by National Institute on Deafness and Other Communication Disorders (NIDCD). The registered enrollment target is 875 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004570 was terminated before completion, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).

TERMINATED
Registry status
875 participants
Enrollment target

Study Summary

Some children with certain language disorders may not properly process the sounds they hear, resulting in language impairments. The purpose of this study is to determine if deficits in auditory temporal processing the way the brain analyzes the timing and patterns of sounds are an inherited trait. Families with auditory temporal processing deficits are sought in order to identify the genes responsible for auditory temporal processing deficits. Children and adults with a diagnosis or history of language impairment in the family and their family members both affected and non-affected are eligible for this two-part study. In Part 1, participants undergo a series of language tests and listening tests to measure various characteristics of how they perceive sound. In Part 2, they are interviewed about language disorders, learning disabilities, and other medical problems of family members. This information is used to construct a pedigree (family tree diagram) showing the pattern of inheritance of family traits. Study subjects whose pedigree indicates that language disorders may be hereditary in their family will provide either a small blood sample (1 to 2 tablespoons) or a tissue specimen obtained from a cheek swab (rubbing the inside of the cheek with a small brush or cotton swabs). The sample will be used to isolate DNA for genetic analysis.

Trial Details

FieldValue
Enrollment Target 875 participants
Start Date 1999-01-31
Est. Completion 2018-09-18

Why NCT00004570 stopped before completion

NCT00004570 is an observational study that tracks outcomes without assigning an intervention. The registered 875 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00004570 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00004570 about?

NCT00004570 is a clinical study titled "Hereditary Deficits in Auditory Processing Leading to Language Impairment". Some children with certain language disorders may not properly process the sounds they hear, resulting in language impairments. The purpose of this study is to determine if deficits in auditory temporal processing the way the brain analyzes the timing and patterns of sounds are an inherited trait. ...

What is the current status of trial NCT00004570?

This trial is currently terminated. The enrollment target is 875 participants. The study started on 1999-01-31. Estimated completion is 2018-09-18.

Who is sponsoring clinical trial NCT00004570?

This trial is sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD), which has 34 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07076199 · 877 participants · Phase 3

    A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

  • NCT06627647 · 878 participants · Phase 3

    A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

  • NCT05174286 · 880 participants · NA

    Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk

  • NCT05454280 · 880 participants · Phase 3

    Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00004570, the US trial registry maintained by the National Library of Medicine. NCT00004570 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.